CD BioGlyco has been working on glycomedicine development for many years. We have developed systematic solutions to provide customers with glycomedicine development services based on targeting carbohydrates of pathogens. Welcome customers from all over the world to cooperate with us!

Pathogens

Infectious diseases are caused by pathogens, which include bacteria, fungi, protozoa, worms, viruses, and even infectious proteins called prions. Pathogens of all classes must have mechanisms for entering their host and for evading immediate destruction by the host immune system. In humans and animals, enteric pathogens, which include viruses, bacteria and protozoa, infect the intestine epithelial lining, resulting in food poisoning or diarrheal disease. When enteric pathogens enter humans or animals via the oral route, they must withstand the proteolytic conditions in the stomach before penetrating the mucus layer and accessing the underlying gut epithelium for attachment or cell invasion. Adhesion of the enteric pathogens to the intestine epithelial tissue is a prerequisite for the initiation of infection. In many systems, it is mediated by lectins present on the surface of the pathogen that bind to complementary carbohydrates on the surface of the host cells.

Development of Carbohydrate-based Therapeutic Drugs

Once pathogens invade the host cells, they initiate their survival mechanisms to avoid extermination by host immunity. Ultimately, if infection of host cells could be inhibited, proliferation of the pathogens could be prevented and pathogenesis could be controlled. Insights to address this concept will be invaluable to developing novel therapies using innovative drug design and engineered vaccine candidates, to limit the infectivity of widespread enteric pathogens. One approach to develop effective prophylactic and therapeutic antimicrobial agents is to modify the drug structure. Another approach is to modify the mode of inhibition of infection depending on the individual pathogen by using and mimicking the interactions with carbohydrates. We are committed to the development of therapeutic drugs for the treatment of diseases caused by pathogens.

Fig.1 Nature of pathogenic agents binding to carbohydrate ligands on host cell surfaces. (Utratna, et al.,2016)

Glycomedicine Development Services Based on Targeting Carbohydrates of Pathogens

At CD BioGlyco, we pay attention to every detail in carbohydrate-based glycomedicine development and strive for perfection in every process, evidenced by our many years of successful experience.

For carbohydrate-based antiparasiti development, we offer glycosylphosphatidylinositol (GPI) modification service, focusing on designing the sulfated positions in the carbohydrates, which be critical for the inhibitory quality. Moreover, we are committed to the development of antiviral glycomedicines including important antibiotics, for example, the design of sialic acid analogs as neuraminidase inhibitors to block the invasion of influenza A and B. In addition, we provide efficient pathogen detection services at the point of use, such as PCR-based techniques, antibody-based methods (enzyme-linked immunosorbent assays or fluorescent antibody assays), microcantilevers, evanescent wave biosensors, immunosorbent electron microscopy, atomic force microscopy and biosensors.

Advantages of Us

• Custom glycomedicine development services.
• Update methods according to international development.
• The efficient and rapid detection technology.
• Systematic operation and powerful analysis platform.

With the advanced carbohydrate-based glycomedicine development platform, CD BioGlyco is committed to glycomedicine development based on targeting carbohydrates of pathogens. We have provided solutions for many scientists all over the world. High-quality and efficient services have won us a lot of praise. If you are interested in our services, please contact us to obtain more information.

Reference:

1. Utratna, M.; et al. Exploitation of glycobiology in anti-adhesion approaches against biothreat agents. Journal of Bioterrorism & Biodefense. 2016, 7(2).